Please login to the form below

Not currently logged in
Email:
Password:

Recordati

This page shows the latest Recordati news and features for those working in and with pharma, biotech and healthcare.

FDA approves Recordati’s Cushing disease drug Isturisa

FDA approves Recordati’s Cushing disease drug Isturisa

Recordati is expecting peak sales of Isturisa of more than $100m a year, according to chief executive Andrea Recordati. ... Patent protection extends to 2031 for Isturisa and 2026 for Signifor LAR, according to Recordati, which had total revenues of

Latest news

More from news
Approximately 4 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    AstraZeneca, Takeda, Astellas Pharma, Novo Nordisk and Recordati take up the final five positions, though only two - Takeda (3.9%) and Astellas (9.3%) - recorded growth.

  • Deal Watch July 2016 Deal Watch July 2016

    BioD. $21.3 plus $56.5 contingent. $22m. 3.5x. N/A. Recordati. Pro Farma. ... Recordati has been busy on the acquisition front recently; in May the company acquired Italichimici for $145m, strengthening its gastroenterology and respiratory ranges, and

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    4. ). 63. Apricus Biosciences (formerly NexMed) / Recordati. Licence. Vitaros topical treatment for erectile dysfunction.

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    246. Laboratorios Casen Fleet/ Recordati. Acquisition. Spanish pharmaceutical company. 123. Pacific Biosciences of California/Roche Diagnostics.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    50. Opalia Pharma / Recordati .  Acquisition of 90% stake. Branded generic drugs - dermatology, GI, respiratory.

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Recordati promotes Andrea Recordati to COO Recordati promotes Andrea Recordati to COO

    Milan-based pharmaceutical company Recordati has promoted Andrea Recordati (pictured right) to chief operating officer. ... In his newly-created position, Andrea Recordati will be responsible for all the group's commercial and production activities.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics